NEW YORK (GenomeWeb News) – Gentel Biosciences today said that it has acquired the SilverQuant trademark from Eppendorf, which it will apply to its protein array technology platform.
Madison, Wis.-based Gentel said the acquisition of the trademark complements its other initiatives to grow its market position as a provider of multiplexed proteomic tools.
In 2008, Gentel had acquired from Eppendorf the rights to array-based chromogenic detection technology that uses gold particle-enhanced silver crystal deposition for detection and quantification of arrays. Today, it said that the SilverQuant technology works with the Gentel Proteomics Multi-System, which integrates chromogenic scanning and analysis of arrays at a price comparable to a benchtop ELISA system.
"The SilverQuant name accurately describes our unique chromogenic detection technology as well as its application to protein quantitation," Gentel VP of Commercial Development Dan Clutter said in a statement. "Further, SilverQuant is a strong trademark that adds a valuable intangible asset to the company given its worldwide registration and existing prestige in the life sciences."
Financial terms of the trademark acquisition were not disclosed.